Wuxi Biologics has reported a full-year net income of 3.40 billion yuan, falling short of the estimated 3.58 billion yuan. The company’s revenue exceeded estimates, coming in at 17.03 billion yuan against an estimated 16.98 billion yuan. Adjusted net income surpassed estimates, with Wuxi Biologics reporting 4.70 billion yuan against an estimated 4.2 billion yuan. The gross margin for the c...
藥明康德股票討論區
JUST IN:
NBS:
Revenue growth at industrial enterprises picked up markedly as market demand continued to recover and industrial output expanded rapidly, which created favorable conditions for their profits.
Some 29 out of China's 41 main industries saw profits rise in the first two months.
$阿里巴巴(BABA.US)$$阿里巴巴-SW(09988.HK)$$騰訊控股(00700.HK)$$小米集團-W(01810.HK)$$京東集團-SW(09618.HK)$$百度集團-SW(09888.HK)$$比亞迪股份(01211.HK)$$商湯-W(00020.HK)$$中國石化(600028.SH)$
Wuxi Biologics Earnings Report: FY Net Income Misses Estimates Despite Revenue Surpassing Predictions
The company’s revenue exceeded estimates, coming in at 17.03 billion yuan against an estimated 16.98 billion yuan.
Adjusted net income surpassed estimates, with Wuxi Biologics reporting 4.70 billion yuan against an estimated 4.2 billion yuan.
The gross margin for the c...
暫無評論